DYN Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -2.32%, SMA50 -8.75%, SMA200 7.7%). The stock’s 14-day RSI is 45.42 (neutral), while the ATR of 0.91 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -35.24% below its high and over 154.56% above its low. Average 10-day trading volume of 1.62 million shares is in line with the 3-month average of 1.79 million, indicating normal recent market interest.

Dyne Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $6.80. This means the shares are trading above this model’s fair value.

Dyne Therapeutics, Inc. has 142.26 million shares outstanding. The public float is 122.63 million shares, elevated short interest at 12.59% of float. This equals 16.04 million shares. The short ratio is 5.24 days. Institutional investors hold 95.92% of the float. Insiders own 0.49%. Kersten Dirk holds 4.20 million shares, VV Manager II, LLC has 2.88 million shares and RA CAPITAL MANAGEMENT, L.P. has 2.81 million shares. Over the past six months, insider transactions show net selling. They sold 1.05 million shares across 27 transactions.

Dyne Therapeutics, Inc. (NASDAQ:DYN) closed at $17.67 USD, losing -$0.25 (-1.40%) from the previous close of $17.92. The stock is currently mid-range between its 52-week high and low $8.06 and $25.00. With a market capitalization of about $2.92 billion, Dyne Therapeutics, Inc. is classified as a mid-cap and shows market-like volatility (beta ~1.08). Key stats such as the average daily volume over the past year has been around 1.79 million shares, volume is running light vs its 52-week average. Headquartered in Waltham, MA, Dyne Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO John G. Cox, the company employs approximately 192 people and listed since September 17, 2020. Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders.

Dyne Therapeutics, Inc. generated EPS of -$3.66 over the past year. Five-year average earnings growth is -59.45%. Wall Street analysts project EPS growth of 7.52% annually over the next five years. The latest quarter delivered EPS of -$0.73. The next quarter is forecast at -$0.75. Next year's EPS is expected at $18.82. Analyst sentiment is bullish. Analyst rating data shows there are 11 Strong Buy ratings, 12 Buy ratings, 6 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $60.00 to $9.00. The high target offers 239.56% upside. The low target suggests -49.07% downside. The mean target is $34.07. This offers 92.81% upside. Dyne Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended May 11, 2026, missed forecasts by -5.48%. The prior quarter beat by 2.7%. Over the last six quarters, Apple has recorded several small beats. These include -4.35% in February 27, 2025.

Dyne Therapeutics, Inc. (NASDAQ:DYN) shares are down -15.24% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Dyne Therapeutics, Inc. trading at a premium to the broader market with a P/E of -6.45. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $37.87, suggesting 114.32% upside. Our AI forecast model points to short-term strength (1.02% over two weeks), a medium-term fall (-57.95% over three months), and a longer-term gain (9.9% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Dyne Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 1.02%, with price expected at $17.85 by June 24, 2026, within a range of $16.87 to $18.85 3-Month Outlook: Projected fall of -57.95%, reaching $7.43 by September 08, 2026, with a range of $6.60 to $8.13. 1-Year Outlook: Projected gain of 9.9%, with price at $19.42 by June 10, 2027, within a range of $15.35 to $22.80.

Dyne Therapeutics, Inc. trades at a P/E ratio of -6.45, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 3.37 trading at moderately above to book value. The P/FCF stands at -6.32, also below market averages.